Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USA.
Clin Pharmacol Ther. 2012 Mar;91(3):450-8. doi: 10.1038/clpt.2011.306. Epub 2012 Jan 25.
To develop a benchmark measure of US physicians' level of knowledge and extent of use of pharmacogenomic testing, we conducted an anonymous, cross-sectional, fax-based, national survey. Of 397,832 physicians receiving the survey questionnaire, 10,303 (3%) completed and returned it; the respondents were representative of the overall US physician population. The factors associated with the decision to test were evaluated using χ(2) and multivariate logistic regression. Overall, 97.6% of responding physicians agreed that genetic variations may influence drug response, but only 10.3% felt adequately informed about pharmacogenomic testing. Only 12.9% of physicians had ordered a test in the previous 6 months, and 26.4% anticipated ordering a test in the next 6 months. Early and future adopters of testing were more likely to have received training in pharmacogenomics, but only 29.0% of physicians overall had received any education in the field. Our findings highlight the need for more effective physician education on the clinical value, availability, and interpretation of pharmacogenomic tests.
为了开发一种衡量美国医生在药物基因组学检测方面的知识水平和使用程度的基准测试，我们进行了一项匿名的、基于传真的、全国性的、横断面的调查。在收到调查问卷的 397832 名医生中，有 10303 名（3%）完成并返回了问卷；这些受访者具有美国医生总体人群的代表性。使用卡方检验和多变量逻辑回归评估了与检测决策相关的因素。总的来说，97.6%的应答医生同意遗传变异可能会影响药物反应，但只有 10.3%的医生对药物基因组学检测有足够的了解。在过去的 6 个月里，只有 12.9%的医生开了检测，而 26.4%的医生预计在未来 6 个月内开检测。早期和未来的检测采用者更有可能接受过药物基因组学方面的培训，但只有 29.0%的医生接受过该领域的任何教育。我们的研究结果突出表明，需要对医生进行更有效的教育，让他们了解药物基因组学检测的临床价值、可用性和解释。
